Pharmaceuticals
Japan's Heartseed raises $14m Series D
Heartseed, a Tokyo-based biotech start-up specializing in treatments that use cardiac muscle cells to initiate the remuscularization of patients who have suffered heart failure, has raised JPY 2bn (USD 14.3m) in Series D funding.
China's Biomissile secures $28m Series B
Suzhou-based Biomissile has raised CNY 200m (USD 28m) in a Series B funding round led by Kequan Capital. Existing investor Fosun Health Capital re-upped.
China's Drug Farm secures $27m in first tranche of Series C
Drug Farm, a China and US-based developer of treatments for infection and immunological diseases, has raised USD27m in the first tranche of Series C funding led by Shanghai's YD Capital.
China's Coherent Biopharma raises $100m
Chinese cancer-focused biotech developer Coherent Biopharma has raised about USD 100m in Series B funding featuring HM Capital.
IDG leads $59m Series A for China’s Taichu Biotech
Shanghai Taichu Biotechnology, a China-based outsourced drug developer focused on novel treatments, has raised a serious A of CNY 400m (USD59m) led by IDG Capital.
Eight Roads leads $38m round for China biotech player Adcentrx
China and US-based biotech company Adcentrx has raised USD38m in an extended Series A round led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, and Trinity Innovation Fund.
Deal focus: CBC gets counterintuitive in China
CBC Group has helped multiple start-ups move from in-licensing to drug development to commercialisation. With China’s Hasten, it is navigating this tried-and-tested journey in reverse
CBC, Mubadala lead $315m round for China's Hasten Biopharma
Specialist healthcare investor CBC Group and Mubadala Investment have led a USD 315m round for China-based Hasten Biopharmaceutic, with participation from other undisclosed institutional investors.
China's Alebund Pharma gets $145m in debt, equity funding
Alebund Pharmaceuticals has raised close to CNY 200m (USD 29m) in a pre-Series C funding round. Investors include state-owned Yangzhou Guojin Investment and Yangzhou Longchuan Holdings.
JBIC, Mitsui back Singapore's Wellesta
Japan Bank for International Cooperation (JBIC) and Mitsui & Co have invested in Singapore-based Wellesta, a diversified services provider for the regional healthcare industry.
China GPs re-up in ArriVent Biopharma's $155m Series B
Assorted Chinese investors have participated in a USD 155m Series B round for US-headquartered ArriVent Biopharma, which targets drug candidates emanating from emerging biotech hubs, including China.
DEG leads round for Indonesian mRNA vaccine developer
German development finance organisation DEG has contributed USD 8m as the lead investor in a new funding round for Etana Biotechnologies Indonesia, supported by Yunfeng Capital, HighLight Capital, and East Ventures.
China cell therapy developer Neowise raises $29m
Chinese cell therapy company Neowise has raised an extended Series A round of CNY200m (USD 29m) from a group including Oriza Seed Fund Management and Marathon Venture Partners.
Qiming, Ince invest in China, US biotech start-up
Qiming Venture Partners and Ince Capital have led a USD 50m Series B round for China and US-based oncology and autoimmune diseases treatments developer Allorion Therapeutics.
B Capital closes US-Asia healthcare fund on $500m
US and Asia-focused VC firm B Capital has closed its first dedicated sector fund, collecting USD 500m for investments in healthcare.
China vaccine developer Immorna raises $100m
Immorna, a China-based biotech start-up focused on RNA-based therapeutics and vaccines, has raised about USD 100m across two Series A extensions.
China's Oricell secures $45m Series B extension
Qatar Investment Authority (QIA) and RTW Investments, a US-based healthcare investor, have led a Series B extension of USD 45m for Oricell Therapeutics, a China-based drug developer working on CAR-T cell therapies.
Cenova leads $40m Series B for China's Eluminex
China-based healthcare investor Cenova Capital has led a USD 40m Series B round for Eluminex Biosciences, which is developing drugs and regenerative tissue used to treat eye disease and other vision-threatening medical conditions.
Kotak fund invests $129m in India's Biocon
Kotak Mahindra Advisors (KIA), the alternative assets arm of Kotak Mahindra Group, has committed INR 10.7bn (USD 129.4m) to Indian pharmaceuticals manufacturer Biocon to support the latter’s acquisition of a biosimilar business from global healthcare...
China's Structure Therapeutics soars on US debut
Structure Therapeutics, a China and US-based drug developer specialising in novel oral therapeutics, performed strongly on its trading debut following an upsized USD 161.1m NASDAQ IPO.
India's Enzene Biosciences raises $50m
Indian biotech company Enzene Biosciences has raised a USD 50m round featuring Eight Roads Ventures and F-Prime Capital.
China cell therapy developer raises $75m
Iaso Biotherapeutics, a Chinese cell therapy developer focusing on oncology treatments, has raised nearly CNY 500m (USD 75m) in an extended Series C round.
Advent acquires majority stake in India's Suven Pharma
Advent International has agreed to acquire a 50.1% stake in India-listed drug industry supplier Suven Pharmaceuticals for INR 63.1bn (USD 761.5m) with plans to acquire an additional 26%.
KKR buys Japan's Bushu Pharmaceuticals from BPEA EQT
KKR has agreed to buy Japan-based contract drug manufacturer Bushu Pharmaceuticals from BPEA EQT – formerly Baring Private Equity Asia – for an undisclosed sum.